Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
09/2012
09/13/2012US20120231002 Treatment of vasculoproliferative conditions
09/13/2012US20120231001 Preventives/remedies for cancer
09/13/2012US20120231000 Truncated cystine-knot proteins
09/13/2012US20120230999 Bispecific nanobodies as a therapeutic for alzheimer's disease
09/13/2012US20120230998 Ip-10 antibodies and their uses
09/13/2012US20120230997 Anti-factor B antibodies and their uses
09/13/2012US20120230996 Compositions And Methods For Macular Degeneration
09/13/2012US20120230995 Polyspecific binding molecules and uses thereof
09/13/2012US20120230994 Bladder cancer specific ligand peptides
09/13/2012US20120230993 Axl tyrosine kinase inhibitors and methods of making and using the same
09/13/2012US20120230992 Vegf-related protein
09/13/2012US20120230991 Methods and compounds for enhancing anti-cancer therapy
09/13/2012US20120230990 Humanized antibodies against human il-22ra
09/13/2012US20120230989 Methods and materials for treating renal cell carcinoma
09/13/2012US20120230988 Antibody targeting osteoclast-related protein siglec-15
09/13/2012US20120230987 Methods for treating conditions associated with c-fms
09/13/2012US20120230986 Agent and Methods for Reducing Inflammatory Markers
09/13/2012US20120230985 Humanized anti-factor d antibodies and uses thereof
09/13/2012US20120230984 Methods of Treating or Preventing Autoimmune Diseases With 2,4-Pyrimidinediamine Compounds
09/13/2012US20120230983 Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione
09/13/2012US20120230982 High concentration antibody formulations
09/13/2012US20120230981 CH2 Domain Template Molecules Derived From Rational Grafting Of Donor Loops Onto CH2 Scaffolds
09/13/2012US20120230980 OPTIMIZED Fc VARIANTS AND METHODS FOR THEIR GENERATION
09/13/2012US20120230979 NOGO Receptor Binding Protein
09/13/2012US20120230978 Compositions and methods for modulating circadian synchronization
09/13/2012US20120230953 Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
09/13/2012US20120230948 Brachyury polypeptides and methods for use
09/13/2012US20120230947 Biologically active proteins having increased in vivo and/or in vitro stability
09/13/2012US20120230945 Targeted particles and methods of using the same
09/13/2012US20120230944 Stabilization and storage of biological pharmaceutical compositions
09/13/2012US20120230941 Methods for treating nervous system injury and disease
09/13/2012US20120230939 Methods for treating cancer using prostate specific antigen and tumor endothelial marker peptides
09/13/2012US20120230913 Protein nanoparticle dispersions
09/13/2012US20120230912 Antibodies specific for soluble amyloid beta peptide protofibrils and uses thereof
09/13/2012US20120230911 Tnf-alpha binding proteins
09/13/2012CA2829558A1 Pi3 kinase inhibitors and uses thereof
09/13/2012CA2829367A1 Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
09/13/2012CA2829128A1 Factor xii inhibitors for the treatment of silent brain ischemia and ischemia of other organs
09/13/2012CA2829118A1 Wound healant system and methods of use
09/13/2012CA2829037A1 Factor xii inhibitors for the administration with medical procedures comprising contact with artificial surfaces
09/13/2012CA2828940A1 Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
09/13/2012CA2828787A1 Conjugation process
09/13/2012CA2828583A1 Oral bacteria and uses thereof
09/13/2012CA2828374A1 Oligosaccharides and oligosaccharide-protein conjugates derived from clostridium difficile polysaccharide ps-ii, methods of synthesis and uses thereof, in particular as a vaccine
09/13/2012CA2827759A1 Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution
09/12/2012EP2497831A1 TB vaccination using HCMV-based vaccine vectors
09/12/2012EP2497829A1 Super-agonistic anti-CD-28 antibodies
09/12/2012EP2497826A1 Method of producing a temperature sensitive (ts) influenza virus
09/12/2012EP2497783A2 Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
09/12/2012EP2497782A1 Anti oligomer antibodies and uses thereof
09/12/2012EP2497779A1 Klebsiella antigens
09/12/2012EP2497497A1 Improved adjuvant therapy of G250-expressing tumors
09/12/2012EP2497496A2 Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
09/12/2012EP2497495A2 Making influenza virus vaccines without using eggs
09/12/2012EP2497494A2 Vaccines for the treatment of neoplasias from viral capsids of birnavirus containing antigens of the human papillomavirus
09/12/2012EP2497493A1 Nebulizable tuberculosis vaccine for transnasal administration comprising paramyxovirus vector
09/12/2012EP2497492A1 Genetically engineered swine influenza virus and uses thereof
09/12/2012EP2497491A1 Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses
09/12/2012EP2497489A1 Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
09/12/2012EP2497480A1 Extracts from phototropic microorganisms as adjuvants
09/12/2012EP2497479A1 Extracts from phototropic microorganisms as adjuvants
09/12/2012EP2496609A2 Chimeric rsv-f polypeptide and lentivirus or alpha-retrovirus gag-based vlps
09/12/2012EP2496605A1 Ror1 as therapeutic and diagnostic target
09/12/2012EP2496604A1 Canine anti-cd20 antibodies
09/12/2012EP2496267A2 Zwitterionic polymer bioconjugates and related methods
09/12/2012EP2496265A1 Vaccine compositions and methods of use
09/12/2012EP2496257A1 Treatment of cancer involving mutated kras or braf genes
09/12/2012EP2496256A2 Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines
09/12/2012EP2496255A1 Adjuvanted nanoparticulate influenza vaccine
09/12/2012EP2496254A2 Haemophilus parasuis polypeptides and methods of use
09/12/2012EP2496253A1 Apparatus and method for cryogranulating a pharmaceutical composition
09/12/2012CN102666860A Reverse genetics systems
09/12/2012CN102666843A Wo2011079073
09/12/2012CN102666586A Drug fusions and conjugates with extended half life
09/12/2012CN102666585A Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
09/12/2012CN102666583A 革兰氏阳性细菌特异性结合化合物 Gram-positive bacteria-specific binding compound
09/12/2012CN102666571A Conserved escherichia coli immunogens
09/12/2012CN102665759A Humanized antibodies against human il-22ra
09/12/2012CN102665758A Dock-and-lock (DNL) Complexes For Delivery of Interference RNA
09/12/2012CN102665757A Delivery system for cytotoxic drugs by bispecific antibody pretargeting
09/12/2012CN102665756A Method of treatment of philadelphia chromosome positive leukaemia
09/12/2012CN102665755A Immunopotentiator-linked oligomeric influenza immunogenic compositions
09/12/2012CN102665739A Modified gram-negative bacteria for use as vaccines
09/12/2012CN102665738A Prophylactic composition for influenza infection
09/12/2012CN102665687A Hepatitis B virus antigen formulation for cell stimulation followed by therapeutic immunization
09/12/2012CN102660578A PCV2 immunogenic compositions and methods of producing such compositions
09/12/2012CN102660551A VHH (variable domain of heavy chain of heavy-chain antibody) antibody gene derived from anti-CyPA (CyclophilinA) animal of family Camelidae, encoded polypeptide, and application thereof
09/12/2012CN102659946A Anti-alpha v beta 6 antibodies
09/12/2012CN102659945A Anti-C5aR antibodies and uses thereof
09/12/2012CN102659944A IL-18 binding proteins
09/12/2012CN102659943A Antibody glycosylation in the variable region
09/12/2012CN102659941A Binding molecules
09/12/2012CN102659940A 结合分子 Binding molecules
09/12/2012CN102659931A Immunoenhancer and preparation method
09/12/2012CN102659926A Pc-E polypeptide inhibiting aspergillus fumigatus from adhering to cornea
09/12/2012CN102659925A Human oocyte zona pellucida (ZP)-4 epitope minimum motif peptide identified by anti-recombinant human ZP4N and ZP4C polyclonal antibody
09/12/2012CN102659923A Epitope minimal motif peptides of human zona pellucida protein-4 and extended short peptides and application thereof
09/12/2012CN102659922A Peptide Derived From Hepatitis C Virus
09/12/2012CN102659921A HLA-A*0201 restrictive CTL epitope of neuritin protein, and application of HLA-A*0201 restrictive CTL epitope
09/12/2012CN102657870A Vaccine cryoprotectant without composition of gelatin and human albumin
1 ... 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 ... 1823